文献速递免疫规划妇幼与学校卫生

孕妇三价流感疫苗接种与不良胎儿结局的随机对照试验

Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes.
PubMed 文献 · Vaccine · 2019-07-19

南非一项双盲随机安慰剂对照试验纳入2116名HIV未感染孕妇,于妊娠20至36周接种三价灭活流感疫苗或安慰剂,评估胎儿死亡、低出生体重、小于胎龄儿和早产。结果显示疫苗对上述不良胎儿结局均无显著保护效果,疫苗效力估计值均无统计学意义。

要点

  • 孕妇接种三价灭活流感疫苗未显著降低胎儿死亡风险。
  • 疫苗对低出生体重、小于胎龄儿和早产均无显著保护效果。
  • 限制于流感季节暴露婴儿的分析仍未见疫苗效力。

核心结论

  • 孕妇接种三价灭活流感疫苗对不良胎儿结局未显示出有益效果。

研究设计与样本

  • 南非开展的双盲、随机、安慰剂对照临床试验,2011年3月至2012年流感季节后随访至婴儿24周。
  • 共纳入2116名18至38岁HIV未感染孕妇,妊娠20至36周接种疫苗或安慰剂。
  • 2005名婴儿的母亲在分娩前至少14天接种疫苗或安慰剂,共记录6例流产和23例死产。

主要发现

  • 疫苗对胎儿死亡的效力为-21.2%(95%CI -150.8至41.4),无显著意义。
  • 疫苗对低出生体重的效力为-11.1%(95%CI -42.3至12.5),无显著意义。
  • 疫苗对小于胎龄儿的效力为-9.9%(95%CI -35.6至11.0),无显著意义。
  • 疫苗对早产的效力为-21.3%(95%CI -60.5至8.3),无显著意义。
  • 限制于流感季节暴露婴儿(1832个结局)的分析仍未显示疫苗效力。

临床怎么用

  • 预防医学与公共卫生医生应知晓本试验未发现孕妇接种三价灭活流感疫苗对不良胎儿结局的有益效果。
  • 该结果不改变现有流感疫苗接种推荐,但可为孕期免疫获益的沟通提供证据参考。

局限性

  • 所有分析除胎儿死亡外均排除妊娠34周后接种疫苗或安慰剂的母亲。
  • 研究仅纳入HIV未感染孕妇,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The purpose of this study was to evaluate the association of influenza vaccine during pregnancy and adverse fetal outcomes. Preventing fetal death, low birth weight, small for gestational age birth and preterm birth are important potential effects of antenatal maternal influenza immunization for which there are conflicting data. MATERIALS AND METHODS: A double-blind, randomized, placebo-controlled clinical trial of trivalent inactivated influenza vaccine was conducted in South Africa from March 2011 until after the 2012 influenza season when the infants born had reached the age of 24 weeks. Mothers were administered the vaccine or placebo during pregnancy at a gestation of 20 to 36 weeks. A comparison of rates of fetal death, low birth weight, small for gestational age birth, and preterm birth, between vaccinated and placebo groups was made. Fetal outcome differences between the groups were measured using Student's t-tests, vaccine efficacy with 95% confidence intervals, and Poisson regression for incidence rates. All analyses except fetal death excluded mothers who were administered vaccine or placebo after 34 weeks gestational age. RESULTS: There were 2116 HIV-uninfected pregnant women age 18 to 38 years in the trial; 2005 infants were born to mothers where vaccine or placebo had been administered ≥ 14 days prior to delivery, and there were 6 miscarriages and 23 stillbirths. There was no significant vaccine efficacy (with [95% confidence interval]) on fetal death (-21.2% [-150.8, 41.4]), low birth weight (-11.1% [-42.3, 12.5]), small for gestational age birth (-9.9% [-35.6, 11.0]), or preterm birth (-21.3% [-60.5, 8.3]). Neither was vaccine efficacy demonstrated when the analysis was restricted to infants of mothers who were exposed to an influenza season (1832 outcomes available). CONCLUSION: We did not find a beneficial effect of trivalent inactivated influenza vaccine during pregnancy on adverse fetal outcomes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Simões EAF, Nunes MC, Carosone-Link P, et al. Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. Vaccine. 2019. PMID: 31331777. doi:10.1016/j.vaccine.2019.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。